These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2601625)

  • 1. Preparation and use of anti-idiotypic antibodies armed with holotoxins or hemitoxins in treatment of B-cell neoplasms.
    Bridges S; Longo DL; Youle RJ
    Methods Enzymol; 1989; 178():356-68. PubMed ID: 2601625
    [No Abstract]   [Full Text] [Related]  

  • 2. Intra-thecal treatment of leptomeningeal lymphoma with immunotoxin.
    Urch CE; George AJ; Stevenson GT; Bolognesi A; Stirpe F; Weller R; Glennie MJ
    Int J Cancer; 1991 Apr; 47(6):909-15. PubMed ID: 2010234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies in the treatment of lymphoma.
    Harvey ML; Illidge T; Johnson P
    Clin Oncol (R Coll Radiol); 2001; 13(4):251-61. PubMed ID: 11554621
    [No Abstract]   [Full Text] [Related]  

  • 4. Biologicals for cancer treatment: monoclonal antibodies.
    Levy R
    Hosp Pract (Off Ed); 1985 Nov; 20(11):67-74, 77, 80-4 passim. PubMed ID: 3932392
    [No Abstract]   [Full Text] [Related]  

  • 5. Current applications of monoclonal antibodies for the therapy of hematopoietic cancers.
    Scheinberg DA
    Curr Opin Immunol; 1991 Oct; 3(5):679-84. PubMed ID: 1661602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Selective cytotoxicity of antibody-ricin-A-chain conjugate for human tumor B cells. II. Comparison of activity of immunotoxins conjugated with poly- and monoclonal antibodies].
    Tonevitskiĭ AG; Zhukova OS; Rakhmanova VA; Arsen'eva EL; Bogacheva GT
    Mol Biol (Mosk); 1988; 22(4):911-6. PubMed ID: 3141780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
    Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
    Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Derivatives of anti-idiotype antibodies in the treatment of B-cell lymphoma.
    Glennie MJ; Stevenson GT
    Adv Exp Med Biol; 1985; 186():843-53. PubMed ID: 3876727
    [No Abstract]   [Full Text] [Related]  

  • 9. Molecules recognized by anti-idiotypic monoclonal antibodies to the B cell lymphoma, BCL1.
    Tamura GS; McGrath MS; Weissman IL
    J Mol Cell Immunol; 1987; 3(4):243-53. PubMed ID: 3509925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Serotherapy of leukemia and lymphoma using monoclonal antibodies].
    Rupniewska ZM
    Pol Tyg Lek; 1985 Aug; 40(33):942-7. PubMed ID: 2997760
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of anti-idiotypic antibodies to treat lymphoid tumors.
    Stevenson GT
    Methods Enzymol; 1989; 178():341-55. PubMed ID: 2481211
    [No Abstract]   [Full Text] [Related]  

  • 12. Selective immunotoxins prepared with mutant diphtheria toxins coupled to monoclonal antibodies.
    Colombatti M; Dell'Arciprete L; Rappuoli R; Tridente G
    Methods Enzymol; 1989; 178():404-22. PubMed ID: 2513466
    [No Abstract]   [Full Text] [Related]  

  • 13. Antibody therapy of malignancy.
    Dyer MJ
    Eur J Cancer; 1992; 28(1):276-80. PubMed ID: 1567679
    [No Abstract]   [Full Text] [Related]  

  • 14. Emergence of immunoglobulin variants following treatment of a B cell leukemia with an immunotoxin composed of antiidiotypic antibody and saporin.
    Glennie MJ; McBride HM; Stirpe F; Thorpe PE; Worth AT; Stevenson GT
    J Exp Med; 1987 Jul; 166(1):43-62. PubMed ID: 3110351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of anti-idiotypic antibody-drug conjugates to treat experimental murine B-cell tumors.
    Hurwitz E; Haimovich J
    Methods Enzymol; 1989; 178():369-75. PubMed ID: 2601626
    [No Abstract]   [Full Text] [Related]  

  • 16. Selective cytotoxic activity of immunotoxins composed of a monoclonal anti-Thy 1.1 antibody and the ribosome-inactivating proteins bryodin and momordin.
    Stirpe F; Wawrzynczak EJ; Brown AN; Knyba RE; Watson GJ; Barbieri L; Thorpe PE
    Br J Cancer; 1988 Nov; 58(5):558-61. PubMed ID: 3265330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Manipulation of the immune response by monoclonal antibodies in auto-immune pathology.
    Benoit P; Boucheix C
    Curr Eye Res; 1990; 9 Suppl():201-5. PubMed ID: 2200645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies as carriers of toxins.
    Uhr JW; Fulton RJ; Till MA; May RD; Vitetta ES
    Prog Clin Biol Res; 1989; 288():403-12. PubMed ID: 2785694
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody.
    Foon KA
    N Engl J Med; 1982 Sep; 307(11):686-7. PubMed ID: 6981064
    [No Abstract]   [Full Text] [Related]  

  • 20. Modern immunotherapy of cancer.
    Ravikumar TS; Steele GD
    Adv Surg; 1991; 24():41-68. PubMed ID: 1996529
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.